Product Description
GEFTINIB API
Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Tags :- Gefitinib Manufacturer, Gefitinib Manufacturer in India,Gefitinib Supplier, Supplier in India, Gefitinib Distributor, GefitinibDistributor in India, Gefitinib Merchant Exporter, Gefitinib Exporter,Gefitinib Exporter in India, api, apis, Pharmaceutical Ingredients, ActivePharmaceutical Ingredients, Gefitinib Bulk Drugs manufacturer, Gefitinib BulkDrugs, Gefitinib Bulk drugs in India, Gefitinib Api in India, Bulk Drugs, BulkDrugs in India.
Therapeutic ApplicationGEFTINIB is recognized for its potent antineoplastic activity, making it a valuable treatment option for patients with certain cancer types, such as non-small cell lung cancer. By inhibiting specific pathways involved in cancer cell growth, GEFTINIB contributes significantly to cancer management strategies.
Reliable Manufacturing and SupplyAs a trusted manufacturer and distributor in India, we follow stringent quality assurance processes to guarantee the efficacy and safety of GEFTINIB. Our robust supply chain and export practices make this medication accessible to various institutions, ensuring patients and healthcare providers can reliably source GEFTINIB.
FAQ's of Gefitinib:
Q: How does GEFTINIB work in the body?
A: GEFTINIB functions by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is crucial in the growth and survival of cancer cells. By blocking these signals, GEFTINIB helps slow down or stop tumor progression.
Q: What are the primary uses of GEFTINIB?
A: GEFTINIB is primarily utilized for its antineoplastic activity in the treatment of non-small cell lung cancer (NSCLC). Its targeted action makes it suitable for specific patient populations identified by certain genetic mutations.
Q: When is GEFTINIB typically administered in cancer therapy?
A: GEFTINIB is generally prescribed after diagnostic confirmation of EGFR mutation in patients with NSCLC, and it can be used as a first-line therapy or following other treatment regimens, depending on individual patient profiles.
Q: Where can GEFTINIB be sourced in India?
A: GEFTINIB can be obtained through licensed dealers, distributors, exporters, manufacturers, suppliers, traders, and wholesalers across India. Ensure procurement from authorized sources for quality assurance.
Q: What is the process for manufacturing GEFTINIB?
A: Manufacturing GEFTINIB involves precise chemical synthesis under stringent pharmaceutical standards to maintain its medicine grade and antineoplastic properties. Our facilities adhere strictly to quality protocols to ensure product integrity.
Q: How is GEFTINIB typically administered to patients?
A: GEFTINIB is usually administered orally in tablet form, allowing for convenient dosing. Dosages are determined by medical professionals based on cancer type, stage, and patient-specific factors.
Q: What are the main benefits of using GEFTINIB in oncology treatment?
A: The main benefits of GEFTINIB include targeted therapy with reduced side effects compared to conventional chemotherapy, improved outcomes in EGFR mutation-positive NSCLC patients, and a convenient oral administration route.